Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Bullous pemphigoid (BP) is the most common autoimmune blistering disorder. Its presentation is polymorphic.
Objective: To investigate different clinical and biological profiles of BP.
Methods: We conducted a retrospective 2-center study including all BP patients seen between January 1, 2015, and February 28, 2021. We performed hierarchical clustering on principal components.
Results: Three clusters were identified. Patients in cluster 1 (n = 155) were older than those in clusters 2 (n = 89) and 3 (n = 35; P < .0001), more frequently presented pauci-bullous BP (n = 63 [41%] vs 14 [16%] and 2 [6%], respectively; P < .0001) and had anti-BP230 antibodies in 87% of cases. More than 100 blisters were observed in 14 patients (40%) from cluster 3, versus 3 (2%) from cluster 1 and 0 (0%) from cluster 2 (P < .0001). Frequency of mucosal involvement was higher in cluster 3 (n = 32 [91%, including epiglottis in 40%] vs 11 [7%] and 34 [38%]; P < .0001). In clusters 2 and 3, 70% and 74% of patients had antibodies targeting only BP180. Those in cluster 3 received more lines of systemic treatment and experienced more relapses.
Limitations: Retrospective study without immunoelectron microscopy.
Conclusion: We identified 3 different BP clusters, including one corresponding to severe BP180 BP230 BP with features common to mucous membrane pemphigoid.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jaad.2022.04.029 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Are the dermatological cut-off values of commercially available ELISAs for BP180-NC16A appropriate when applied for diagnosis of oral mucous membrane pemphigoid?. Results of a preliminary study.
Minerva Dent Oral Sci
September 2025
Division of Dermatology Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna Italy.
Background: Enzyme-linked immunosorbent assay (ELISA) kits for BP180-NC16A use different cutoff levels established for cutaneous bullous pemphigoid (BP). However, in oral mucous membrane pemphigoid (OMMP), circulating antibodies are reported to be less readily detectable than cutaneous BP and there is little evidence that these cut-off levels are suitable for OMMP. This study was performed to explore whether the available cutoff values of anti-BP180-NC16A ELISA used for cutaneous BP are equally effective when applied to OMMP or should benefit from an optimized cut-off value.
View Article and Find Full Text PDFCoexistence of bullous pemphigoid, intrahepatic cholangiocarcinoma, and alopecia areata: a case report of multifactorial autoimmunity in a surgical context.
Front Immunol
September 2025
Department of Dermatology, The National Center for the Integration of Traditional Chinese and Western Medicine, China-Japan Friendship Hospital, Beijing, China.
Background: Bullous Pemphigoid (BP) is caused by a predominantly Th2-mediated attack on the basement membrane by the production of anti-BP180 and anti-BP230 antibodies. Malignant tumors can exacerbate immune disorders through a variety of potential pathways, including pro-inflammatory responses in the tumor microenvironment, cross-immune responses induced by tumor-associated antigens, and the lifting of immunosuppressive states and activation of underlying autoimmune responses after surgery. Alopecia Areata (AA) is an autoimmune disease caused by T-lymphocyte-mediated destruction of the immune privilege of the hair follicle, specifically involving the immune axes of Th1, Th2 and Th17.
View Article and Find Full Text PDFA Longitudinal Case Study of Recurrent Pyostomatitis-Pyodermatitis Vegetans Followed by the Subsequent Development of Bullous Pemphigoid With the Presence of Anti-BP230 Autoantibodies Six Years Later.
Cureus
July 2025
Department of Oral Medicine, Beijing Stomatological Hospital, Capital Medical University, Beijing, CHN.
Pyostomatitis vegetans (PSV) is a rare inflammatory condition that has been strongly associated with inflammatory bowel disease (IBD). Additionally, certain cases of PSV have been reported to co-occur with pyodermatitis vegetans (PDV), resulting in a distinct mucocutaneous manifestation. Herein, we present a clinical case of PSV in a 64-year-old male patient diagnosed with ulcerative colitis (UC).
View Article and Find Full Text PDFA Case of Bullous Pemphigoid Triggered by COVID-19 Infection in a Patient Receiving a Dipeptidyl Peptidase-4 Inhibitor.
Cureus
July 2025
Department of Geriatric and General Internal Medicine, Meitetsu Hospital, Nagoya, JPN.
Dipeptidyl peptidase-4 (DPP-4) inhibitors are widely used for the treatment of type 2 diabetes mellitus. Recently, their association with drug-induced bullous pemphigoid (BP) has attracted increasing attention. In this report, we present a case of an 84-year-old woman who developed BP after COVID-19 infection while taking a DPP-4 inhibitor.
View Article and Find Full Text PDFEmerging drugs for the treatment of bullous pemphigoid: what's new on the horizon?
Expert Opin Emerg Drugs
September 2025
Department of Dermatology, Allergy, and Venerology, University of Lübeck, Lübeck, Germany.
Introduction: Bullous pemphigoid (BP) is the most prevalent autoimmune blistering disorder. It is associated with high mortality partially due to side-effects of immunosuppressive drugs. Development of new therapeutics for BP has turned out to be exceedingly challenging, among others, due to frailty of the patients and heterogeneity of the disease.
View Article and Find Full Text PDF